Rizatriptan Benzoate ODT

FDA Drug Profile — Rizatriptan Benzoate ODT

Drug Details

Generic Name
Rizatriptan Benzoate ODT
Brand Names
Rizatriptan Benzoate ODT
Application Number
ANDA203062
Sponsor
Direct Rx
NDC Codes
2
Dosage Forms
TABLET, ORALLY DISINTEGRATING
Routes
ORAL
Active Ingredients
RIZATRIPTAN BENZOATE

Indications and Usage

Rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use • Rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. • Rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. • Rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of rizatriptan benzoate orally disintegrating tablets have not been established for cluster headache.